Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.120
-0.040 (-1.85%)
At close: Apr 28, 2026, 4:00 PM EDT
2.120
0.00 (0.00%)
After-hours: Apr 28, 2026, 8:00 PM EDT
Protalix BioTherapeutics Employees
Protalix BioTherapeutics had 226 employees as of December 31, 2025. The number of employees increased by 13 or 6.10% compared to the previous year.
Employees
226
Change (1Y)
13
Growth (1Y)
6.10%
Revenue / Employee
$233,381
Profits / Employee
-$29,221
Market Cap
170.81M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Tonix Pharmaceuticals Holding | 142 |
| Cartesian Therapeutics | 75 |
| Precision BioSciences | 68 |
| Acumen Pharmaceuticals | 61 |
| Korro Bio | 58 |
| Corbus Pharmaceuticals Holdings | 36 |
| Unicycive Therapeutics | 22 |
PLX News
- 5 weeks ago - Protalix BioTherapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results - PRNewsWire
- 6 weeks ago - Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 - PRNewsWire
- 7 weeks ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) - GlobeNewsWire
- 3 months ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU - GlobeNewsWire
- 3 months ago - Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU - GlobeNewsWire
- 4 months ago - Protalix BioTherapeutics Letter to Stockholders - PRNewsWire
- 4 months ago - Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - PRNewsWire